IMPROVEMENT OF RECOMBINANT PROTEIN S COST OF GOODS & AFFORDABILITY
|
|
- Eileen Newton
- 8 years ago
- Views:
Transcription
1 IMPROVEMENT OF RECOMBINANT PROTEIN S COST OF GOODS & AFFORDABILITY Li How Chen PhD Senior Director, revo Biologics Inc. USA Sami CHTOUROU PhD Senior Vice President Innovation & Scientific Affairs LFB Biotechnologies France
2 Focus Biotherapeutics medicines Recombinant plasma proteins mabs 2
3 US Healthcare Perspectives US Healthcare spending by 2015 forecast 15% GDP ( $ 4 T) Prescription pharmaceuticals in 2015 forecast $ 446 B (> 11% total healthcare expenses) Biologic drugs expenditure Already accounts for > 14 % pharmaceutical spending CAGR of biologics bill >> than for small molecules 33 % of all drugs in development These trends are clearly unsustainable 3
4 The Economic Perspectives 1. Current situation developed countries Social security systems under pressure Slow down of Economy situation in the EU 2. Future trend Co-payment systems Payments by individuals What is expected: Higher pressure on treatment and manufacturing cost of Biotherapeutics Cheaper copy version of innovator products: Biosimilars More potent products: Biobetter (more potent version of well known products) 4
5 Monoclonal Antibodies Market and Perspectives 1. The major contribution mabs have made to medicine is evidenced by their vigorous and continuing growth: the global mabs market is now valued at $45B, 1. By the end of 2012, there were 40 monoclonal antibodies & derivatives approved and marketed for therapeutic use. 2. This Class of product is now approaching maturity, the first products having been put on the market more than ten years ago 3. However monoclonal antibodies are set to continue increasing in importance because of the ubiquity of antigen-antibody interactions in human health and disease. 5
6 mabs Market 1. Highly concentrated market: the Roche group accounted for >40% of total therapeutic monoclonal antibody sales in therapeutic antibodies of the 40 marketed achieved blockbuster sales of more than US$ 1B. 3. Cost of therapies with mabs are typically much higher than small molecules ($30K - $400K / year; $5K - >$20K / g). 4. Cost pressures will increase as the current original brands approach patent term expiration: creating an opportunity for biosimilars. 6
7 Geographic Breakdown of mabs Markets The USA is the largest regional market representing almost half the global total. Differences between developed and emerging economies are greatest for mabs and therapeutic proteins because of their premium prices. Innovator biologics are typically associated with treatment costs that are well above what can be afforded by the majority of patients in emerging economies 7
8 Non-mAbs Biologics Market Dynamics
9 How to Improve Recombinant Protein CoGs and Affordability 1. Use of an improved expression cell line combined with improved cell (see for more details Antibody Technology Companies 2010, La Merie Business Intelligence on November 1, 2010) 2. Use of an alternative expression system with capacity to reduce the Capex and Opex as the production in the milk of transgenic animals 3. Improve the functionality of the mabs: obtain the same therapeutic effects with less product (enhanced ADCC, enhanced CDC; longer half-life) 9
10 LFB s Approach: 3 Different Platforms EMABLING: High ADCC antibodies by natural glycosylation improvement HuMabFc: effector function modification ADCC, CDC, half-life by Mutagenesis rpro Technology: Biosimilar and Biobetter mabs, recombinant plasma proteins 10
11 ADCC % lysis Glyco-engineered mabs: High ADCC Human Abs glycosylation 40 Target : B-CLL R603-LFB Rituximab n= ng/ml 20 > 5000 ng/ml Mab ng/ml (LOG) EMABling (Strong IP position) Natural glycosylation pattern: - Cell line with low Fuc (EB66, YB2/0) - Tg animal (rabbit) Glycosylation pathway modification : KO/Kin (CHO, Yeast, plant, moss) Silencing (CHO, plant) Use of fucosylation inhibitors during production (Kifunensine) or selection of non fucosylated Mabs during purification 11 11
12 ratio/ ratio/ Fc - WT C Fc Sequence Engineering All Fc mediated functions can be modulated: ADCC/ADPC, CDC and half-life Fc mutagenesis can be immunogenic best situation is with human like sequence or close ADCC /ADPC modulation (FcgR binding) CDC modulation (C1q binding) C half-life modulation (FcRn binding) Random mutagenesis + phage display (No limits in the options) MS2 on FcRn : ratio/wt from 2 to 28 Fc - Phages Anti - M13 HRP ratio/ Fc WT FcRn - p Current Opinion in Biotechnology 2009, 20:
13 rpro Technology 13
14 Our mabs USP Production Units A bioreactor that eats hay 14
15 rpro Technology How it Works Separation Filtration Purification Viral eradication Polishing Fill and finish Packaging Utuximab Utuxin Separation Filtration Purification Viral eradication Polishing Fill and finish Packaging
16 CAPEX & OPEX Considerations $500 million mabs manufacturing plant $25 million Tg mabs manufacturing plant Considerations Significant investment Must be made early in development cycle Additional volumes require New plant (=money) Revalidation (=time and risk) Decision must be made years in advance (=money and risk) Considerations No new capital investment req d Virtually unlimited production capacity Unparalleled flexibility for scale-up No additional costs Short timeframes to add capacity No revalidation (no risk) Validated with US and EU regulatory authority product approval 16
17 Lower Cost & Time Saving of Scaling Up the Production Traditional cell-based protein production vs. Transgenic protein production S U P P L Y Pilot plant Plant #1 Plant #2 Plant #3 S U P P L Y 17
18 rpro Technology s Expected Benefits What are the expected benefits for human healthcare? Providing abundant and cost effective therapeutic recombinant products Contributing in healthcare cost reduction in developed countries Improving access to therapeutic products (availability and affordability) for developing countries
19 Broad Utility for rpro Technology rpro Technology Can Be Harnessed to Produce High Yield Recombinant Versions of a Wide Range of Traditionally Plasma-Derived Proteins Protein Indications Antithrombin ATryn FDA, EMA approved) Hereditary Antithrombin Deficiency Pulmonary Embolism Disseminated Intravascular Coagulation C1 Esterase Inh Ruconest (EMA approved) Hereditary Angioedema Factor VIIa Alpha-Fetoprotein Alpha-1 Antitrypsin Fibrinogen Factor IX Butyrylcholinesterase Albumin Prothrombin Hemophilia Myasthenia Gravis Multiple Sclerosis Alpha-1 Antitrypsin Deficiency Fibrin Glue Hemophilia B Organophosphate Poisoning Volume Replacement Hemostasis
20 ATryn Recombinant Antithrombin Single chain complex glycoprotein - Plays fundamental role in suppression of coagulation - Principal inhibitor of thrombin and factor Xa - Binding of heparin causes a conformation change and 1000 fold increase in inhibitory activity Difficult to express cost-effectively in cell culture (large doses are often required) Anticoagulant and anti-inflammatory properties Hereditary and acquired deficiencies: Hereditary Deficiency (HD, approved ATryn indication) Acquired Deficiency (e.g. DIC, preeclampsia, extra-corporeal circulation, trauma, burns etc Non approved) Regulatory Approvals in 2006 (EMA) and 2009 (FDA) Currently commercialized; ongoing clinical development for acquired deficiency indications.
21 Human FVIIa Development Goal To provide to the global Hemophiliac population an affordable, highly-active rh-fviia therapy for the treatment of Hemophiliac A or B with inhibitors by leveraging our proprietary, highyield, low cost manufacturing technology.
22 Characterization of LFB-rFVIIa Extensive analytical characterization performed and compared to NovoSeven Physiochemical Structural properties Functional Characterization Structural - Comparable γ-carboxylation, Hydroxylation and O-glycosylation - Differences in N-glycosylation - No immunogenic structure Gal-Gal detected. In-Vitro Functional tests performed: * Capacity to bind rstf * Capacity to bind phospholipids * Capacity to activate Factor X * Capacity to generate thrombin *FVII assays : antigen, chronometric & chromogenic In-Vivo PK studies in rabbit with similar half-life Warfarin treated rats similar bleeding times
23 FVIIa activity (ng/ml) FVIIa activity (ng/ml) FVIIa Phase 1b Preliminary PK/PD mcg/kg Time (h) mcg/kg Time (h) 23 23
24 Transgenic Expression of mabs 24
25 Tg Expression Advantage Cell Culture Best Commercial now 1-2 g/l after 14 days, 23X/yr Claim of 10 g/l (DSM) Uncertain achievement in practice Likely significant additional license burden Likely achievable range 1 2, perhaps 5 g/l Expect commercial lines of 2 g/l 2013, up to 5 g/l 2017 GTC Transgenics average ~ 5 g/l Varied Expressions from ~ 1 up to 50 g/l Confident achievement of 3 10 g/l 25
26 Adalimumab Binds to TNFα preventing activation of TNF receptors Important in down-regulating the inflammation associated with autoimmune diseases Third TNF inhibitor to be approved in US after infliximab (Remicade) and etanercept (Enbrel) Abbott Labs Humira approved by FDA in 2002 #1 global biologics therapy: $9.2B in 2012 revo generated transgenic goat lines in 2010 Expression ~20 g/l
27 Arthritic Score Histopathology Score Average Body Weight Adalimumab - Arthritis Model CHO-adalimumab Tg goat-adalimumab Dose of anti-tnf antibody (mg/kg) 1 CHO-adalimumab Tg goat-adalimumab Dose of anti-tnf antibody (mg/kg) 15 CHO-adalimumab Tg goat-adalimumab Dose of anti-tnf antibody (mg/kg) ED 50 (mg/kg) CHO Transgenic Arthritis Score Histopathology Score Source: Kaymakcalan et al. (2002) Poster presented at FOCIS 2002
28 % Lysis % IL-2 Induction Tg anti CD20: A Biobetter anti-cd20 mab ADCC (Antibody Dependent Cellular Cytotoxicity) Key mechanism by which MAbs kill tumor cells enhanced efficacy decreased dosing IL-2 Induction Transgenic-goat MAbs have naturally enhanced ADCC 100 B-CLL Patients B cells Rituxan 0 Rituxan TG20 TG20 (anti-cd20 MAb) TG20 (anti-cd20 MAb) TG20 TG20 (vs. Rituxan) has: significantly enhanced ADCC similar target affinity similar CDC [MAb] (ng/ml) (Log) Anti-CD20 MAb market >$6B Licensed to TG Therapeutics (TGTX) 28
29 Trastuzumab Humanized antibody that binds selectively to the HER2 protein Cancers usually develop resistance to trastuzumab Combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate Treatment cost up to $100,000 per year Sales: >$6.4B in Transgenic production: Transgenic goats: 50 g/l Equivalent binding to Her2 Equivalent ADCC CDC under evaluation
30 Cetuximab Chimeric antibody that binds selectively to the EGFR (epidermal growth factor receptor) Indicated for the treatment of metastatic K-RAS wild-type colorectal as well as for head and neck (squamous cell carcinoma) cancers. Typical treatment cost: ~$80,000 (~$10,000 per month) Worldwide Sales: ~$2 Billion in 2012 Transgenic goats: 10 g/l Equivalent binding to EGFR ADCC and CDC under evaluation Transgenically-derived product is free of a 1-3 Gal residues which cause anaphylaxis observed with Erbitux
31 Three Key Take-aways g/l = Operational Advantages Expression Advantage 5 vs 2 g/l FLEXIBLE SCALE - KG Global Cost Advantages Upstream Capex 10x Total Capex 2x COGS ~= 50-60%, incl royalties LOWER CAPEX HIGHER AVERAGE UTIL% 31
32 Thanks for your attention IMPROVEMENT OF RECOMBINANT PROTEIN S COST OF GOODS & AFFORDABILITY Li How Chen PhD Senior Director, revo Biologics Inc. USA Sami CHTOUROU PhD Senior Vice President Innovation & Scientific Affairs LFB Biotechnologies France
Company Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationBiologics: Specific Drug Safety Challenges. Violetta B. Kyburz
Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationBiosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationMRC Technology Centre for Therapeutics Discovery
MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationChallenges and Opportunities of Monoclonal Antibody Manufacturing in China
BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationTesting Services for Large Molecule Drug Development
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
More informationA customizable ADCC assay service for antibodies & fusion proteins.
Antibody Dependent Cell- Mediated Cytotoxicity (ADCC) Assay A customizable ADCC assay service for antibodies & fusion proteins. Our ADCC assay service accurately detects cell lysis based on LDH-release.
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationMonoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,
More informationWelcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment
Welcome to the Launch of Biocon s Breakthrough Innovation For Psoriasis Treatment PRESS MEET Bangalore, August 10, 2013 Autoimmune Diseases are on the Rise Globally Autoimmune Disease Segment includes
More informationAnimal Pharming: The Industrialization of Transgenic Animals December 1999
Animal Pharming: The Industrialization of Transgenic Animals December 1999 Animal pharming, the process of using transgenic animals to produce human drugs, is staking its claim in a lucrative world market.
More informationEnhancing Anti-Tumor Activity of Checkpoint Inhibition
Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationChallenges in early clinical development of biologics
Challenges in early clinical development of biologics Peter Lloyd March 2011 Acknowledgements: Jennifer Sims, Phil Lowe, Sebastian Spindeldreher, Andrew Warren Protein therapeutics biologics Current generation
More informationBiotherapeutics Drug Development
Biotherapeutics Drug Development Susan Hurst, Ph.D. University of Connecticut Bioanalytical Chemistry Spring 2011 April 19, 2011 Outline Background Therapeutic Modalities Examples of Challenges for Biotherapeutics
More information12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma
12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program
More informationAccelerating Antibody Drug Development Using Novel ADCC Reporter Bioassays. Terry Surowy, PhD Research Manager
Accelerating Antibody Drug Development Using Novel ADCC Reporter Bioassays Terry Surowy, PhD Research Manager Outline Antibody drugs and mechanisms of action (MOA) Introduction to ADCC and ADCC Reporter
More informationScientific Challenges for Development of Biosimilar Monoclonal Antibodies. Rafiqul Islam Director, Global Bioanalytical Services Celerion
Scientific Challenges for Development of Biosimilar Monoclonal Antibodies Rafiqul Islam Director, Global Bioanalytical Services Celerion Presentation outline Biosimilars Definitions and Concepts Regulatory
More informationWhy is FTO important?
Antibodies, Patents and Freedom to Operate: The Monoclonal Maze Timothy J. Shea, Jr. Director Tracy Muller Associate Sterne, Kessler, Goldstein & Fox P.L.L.C. 4 th Annual Antibody Therapeutics Conference
More informationCommercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationGenScript Antibody Services
GenScript Antibody Services Scientific experts, innovative technologies, proven performance We specialize in custom antibody production to empower your research Custom Polyclonal Antibody Production Custom
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationCompany Update. March 2011
Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationNew Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
More informationLABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Secondary Hemostasis CIRCULATORY SYSTEM Low volume, high pressure system Efficient for nutrient delivery to tissues Prone to leakage 2º 2 to endothelial surface
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationKempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011
Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationREFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,
More informationBriefing Paper on Biological and Biosimilar Medicines
Briefing Paper on Biological and Biosimilar Medicines Contents With our thanks IAPO would like to thank all those involved in planning this Toolkit and supporting its development. A full list of acknowledgements
More informationASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.
ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis June 17, 2014 Presiding: Dr. Keyang Xu (Genentech) and Dr. Fabio Garofolo
More informationFederal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights
ADVANCED TE CHNOLOGY P ROGRAM The Advanced Technology Program Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights April 2006 National Institute of Standards and Technology
More informationDU maladies systémiques Biothérapies des maladies systémiques Le 25 mai 2012
DU maladies systémiques Biothérapies des maladies systémiques Le 25 mai 2012 10h-10h10 10h10-10h40 10h40-11h10 11h10-11h40 11h40-12h10 12h10-12h40 -Introduction : Luc Mouthon -Immunoglobulines intraveineuses
More informationTreatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR
Treatment of Rheumatoid Arthritis in the New Millennium Neal I. Shparago, D.O., FACP, FACR What is RA? Symmetric inflammatory polyarthritis Rheumatoid factor positive in 80% Anti-CCP positive in approximately
More informationMedia Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationImplementation of Advanced Chromatography techniques to Mitigate Purification Concerns in Bispecific Monoclonal Antibody Manufacturing
www.beroe- WHITEPAPER December 2012 inc.com Implementation of Advanced Chromatography techniques to Multi Column Solvent Gradient Purification or MCSGP chromatography process is a better solution to Bispecific
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationAffitech A/S reports financial result for the first six months of 2012
Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for
More informationLessons for the United States: Biosimilar Market Development Worldwide
Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationImmunoGenes. Improving Antibody Production Using Genetically Modified Animals. HIPO - April 3-4, 2012
ImmunoGenes Improving Antibody Production Using Genetically Modified Animals HIPO - April 3-4, 2012 Significant Opportunity The $40 billion monoclonal antibody (mab) and $ 4 billion polyclonal antibody
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody
More informationA Comparison of US and EU Biosimilars Regimes
A Comparison of US and EU Biosimilars Regimes summary statement Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different
More informationAntibody Services from GenScript
Services from GenScript www.genscript.com GenScript USA Inc. 860 Centennial Ave., Piscataway, NJ 08854 USA Toll-Free: 1-877-436-7274 Fax: 1-732-210-0262 1-732-885-5878 Academic Services Pharmaceutical
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More information9. WestLB Deutschland Conference. Frankfurt November 16, 2011
9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationAugust 28, 2012. Company Update Commerzbank Sector Conference Week
August 28, 2012 Company Update Commerzbank Sector Conference Week Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationBioMmune Technologies Inc. Corporate Presentation 2015
BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More information2006 Provider Coding/Billing Information. www.novoseven-us.com
2006 Provider Coding/Billing Information 2 3 Contents About NovoSeven...2 Coverage...4 Coding...4 Reimbursement...8 Establishing Medical Necessity and Appealing Denied Claims...10 Claims Materials...12
More informationIP throughout the life cycle of Xencor a biotech company
IP throughout the life cycle of Xencor a biotech company Bassil Dahiyat Ph.D. President and CEO Proteins by Design Xencor snapshot Biopharmaceutical company with proprietary platform technologies 21 US
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationBleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.
Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding may be spontaneous in the form of small haemorrhages into the
More informationThe case for biosimilar monoclonal antibodies: Ask the experts - biosimilar speaker tour
The introduction of biosimilars to the New Zealand health system The case for biosimilar monoclonal antibodies: Ask the experts - biosimilar speaker tour July 2012 1 The case for biosimilar monoclonal
More informationWHITE PAPER. Developing Biosimilars in Emerging Markets: Regulatory and Clinical Considerations
WHITE PAPER Developing Biosimilars in Emerging Markets: Regulatory and Clinical Considerations ppdi.com March 2013 EXECUTIVE SUMMARY Emerging markets in Asia Pacific, Latin America and Eastern Europe are
More informationpåçííáëü=jéçáåáåéë=`çåëçêíáìã==
påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults
More informationAntibody Services from GenScript, Brochure
Services from GenScript, Brochure Interest in any of the products, request or order them at Bio-Connect. Bio-Connect B.V. T NL +31 (0)26 326 44 50 T BE +32 (0)2 503 03 48 Begonialaan 3a F NL +31 (0)26
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationKey Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
More information(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications June 2009 Volume: TMRTMA09-0601 THERAPEUTIC MONOCLONAL ANTIBODIES MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationPh.D. in Molecular Medicine
Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to
More informationTypes, production of antibodies and Antibody/antigen interaction
Types, production of antibodies and Antibody/antigen interaction Antibodies Secreted by B lymphocytes Great diversity and specificity: >109 different antibodies; can distinguish between very similar molecules
More informationPhase 1 Study of ALN-AT3 An Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders.
Phase 1 Study of ALN-AT3 An Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders January 12, 2015 1 Agenda Welcome Cynthia Clayton Vice President, Investor Relations
More informationAbnormal Basic Coagulation Testing Laboratory Testing Algorithms
Global Coagulation Testing Abnormal Basic Coagulation Testing Laboratory Testing Algorithms Jeffrey S. Jhang, M.D. No single global laboratory test Bleeding history is the strongest predictor of bleeding
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More information2) Macrophages function to engulf and present antigen to other immune cells.
Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components
More informationJefferies 2012 Global Healthcare Conference. June 8, 2012
Jefferies 2012 Global Healthcare Conference June 8, 2012 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationTowards Well-Defined ADCs (Antibody Drug Conjugates)
Towards Well-Defined ADCs (Antibody Drug Conjugates) Next generation approach June 10, 2015 Dr. Yong Zu Kim, CEO and President LegoChem Biosciences, Inc. Antibody Drug Conjugates ADC binds to Antigen Endocytosis
More information3 months 1.5 months 1.5 months. 1 month
Rabbit monoclonal antibody (Mab) is secreted by the plasma B-cell of the rabbit. Traditional generation of rabbit Mab relies on a rabbit myeloma for B- cell fusion (
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationWinter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
More information